NicOx spikes on successful glaucoma drug study

Shares of France's NicOx spiked on the news that its experimental glaucoma drug licensed to Bausch & Lomb proved positive in a mid-stage study. According to their release two of the four doses used in the trial worked better than Pfizer's ($PFE) Xalatan to reduce eye-fluid pressure. The upbeat news is a welcome relief for NicOx, which was hammered last year after big regulatory setbacks in the U.S. and Europe for naproxcinod. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.